Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The goal of this single center, double-blinded, placebo-controlled, and randomized Phase 1
trial is to determine if i.v. citicoline is safe and efficacious compared to i.v.
saline/control in adults presenting with SARS CoV-2 infection complicated by acute hypoxemic
respiratory failure. The main questions it aims to answer:
- Is citicoline safe in this patient population?
- Does citicoline have a benefit in terms of improving oxygenation?
- Does citicoline reduce overall severity of illness as reflected by standardized scales.
Patients will be assigned to i.v. treatment with citicoline or saline twice daily for 5
consecutive days. SpO2/FiO2 ratios will be recorded daily as per standard clinical practice
to compare citicoline treatments at three different doses to placebo.